NEW YORK — Shares of Travere Therapeutics Inc. skyrocketed more than 33% in early trading Tuesday after the U.S. Food and Drug Administration granted full approval for the company's drug FILSPARI to treat focal segmental glomerulosclerosis, a rare and progressive kidney disorder with no prior approved therapies.
Travere Therapeutics Stock Soars 33% After FDA Approves FILSPARI as First Drug for Rare Kidney Disease FSGS
